Janssen Pharmaceutical's psoriasis drug achieves primary endpoint in phase 3 trial

Source :: M2 EquityBites (EQB). December 14, 2018
Publication Year :: 2018
Abstract: Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three trial in adults with moderate [...]

Subjects :: Novartis AG -- Product development
Pharmaceutical industry -- Product development
Psoriasis -- Drug therapy
Dermatologic agents -- Product development
Interleukins
Medical research
Business
Cosentyx (Medication)
Tremfya (Medication)

Tools